Ligand-activated transcription factor that forms obligate heterodimers with the retinoic acid receptor and acts as a key regulator of biological processes, such as adipocyte differentiation, lipid metabolism, glucose homeostasis and beta-oxidation of fatty acids (PubMed:16150867, PubMed:20829347, PubMed:23525231, PubMed:8702406, PubMed:8706692, PubMed:9065481). Activated by lipid ligands: binds peroxisome proliferators, such as hypolipidemic drugs, and fatty acids, such as prostaglandin J2 metabolites (PubMed:16150867, PubMed:20829347, PubMed:23525231, PubMed:8702406, PubMed:8706692, PubMed:9065481). Ligand-binding results in a conformational change in the receptor, promoting dissociation of repressors and recruitment of coactivators, and subsequent activation of target gene expression (PubMed:16150867, PubMed:20829347, PubMed:23525231, PubMed:8702406, PubMed:8706692, PubMed:9065481).

Specifically binds to DNA specific PPAR response elements (PPRE) and modulates the transcription of its target genes, such as acyl-CoA oxidase (By similarity). Acts as a critical regulator of gut homeostasis by suppressing NF-kappa-B-mediated pro-inflammatory responses (PubMed:20829347). Plays a role in the regulation of cardiovascular circadian rhythms by regulating the transcription of BMAL1 in the blood vessels (By similarity)

Heterodimer with retinoic acid receptor, such as RXRA (By similarity). The heterodimer with the retinoic acid receptor RXRA is called adipocyte-specific transcription factor ARF6 (By similarity). Interacts with NCOA6 coactivator, leading to a strong increase in transcription of target genes (PubMed:10681503).

Interacts with coactivator PPARBP, leading to a mild increase in transcription of target genes (By similarity). Interacts with NCOA7 in a ligand-inducible manner (PubMed:11971969). Interacts with NCOA1 and NCOA2 LXXLL motifs (PubMed:16919947, PubMed:9744270).

Interacts with ASXL1, ASXL2, DNTTIP2, FAM120B, MAP2K1/MEK1, NR0B2, PDPK1, PRMT2 and TGFB1I1 (PubMed:12039952, PubMed:15047147, PubMed:15687259, PubMed:15976031, PubMed:17101779, PubMed:21047783). Interacts (when activated by agonist) with PPP5C (By similarity). Interacts with HELZ2 and THRAP3; the interaction stimulates the transcriptional activity of PPARG (PubMed:16239304, PubMed:23525231).

Interacts with PER2, the interaction is ligand dependent and blocks PPARG recruitment to target promoters (By similarity). Interacts with NOCT (By similarity). Interacts with FOXO1 (acetylated form) (By similarity).

Interacts with ACTN4 (PubMed:22351778). Interacts (when in the liganded conformation) with GPS2 (By similarity). Interacts with CRY1 and CRY2 in a ligand-dependent manner (By similarity).

In the absence of hormonal ligand, interacts with TACC1 (PubMed:20078863). In macrophages, interacts with PAQR3 and STUB1; these interactions promote PPARG poylubiquitination and STUB1-mediated degradation (By similarity). Interacts with YTDC1 (via its intrinsically disordered region); the interaction prevents the ubiquitin-mediated proteasomal degradation of PPARG (By similarity)

Interacts with CEBPA; promoting activation of the adipogenic program (By similarity). Interacts with PRDM16; promoting activation of brown and beige adipocytes (By similarity)

Highest expression in adipose tissue. Lower in skeletal muscle, spleen, heart and liver. Also detectable in placenta, lung and ovary

The 9aaTAD motif is a transactivation domain present in a large number of yeast and animal transcription factors

• Unknown disease
• Obesity (OBESITY)

  A condition characterized by an increase of body weight beyond the limitation of skeletal and physical requirements, as the result of excessive accumulation of body fat.

• Lipodystrophy, familial partial, 3 (FPLD3)

  An autosomal dominant form of lipodystrophy characterized by marked loss of subcutaneous fat from the extremities. Facial adipose tissue may be increased, decreased or normal. Affected individuals show an increased preponderance of insulin resistance, diabetes mellitus and dyslipidemia.

• Glioma 1 (GLM1)

  Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes.